ABBV 10-K Analysis: The $15 Billion Earnings Illusion Behind 96x P/E
AbbVie buried $15 billion in non-cash charges inside its fiscal 2025 10-K — more than triple its reported net income. The 96x GAAP P/E collapses to 21x on a cash basis, but $25.4 billion in contingent consideration obligations and a franchise concentration reboot (42.3% of revenue in two drugs, heading to 51.5%) reveal the truth sits between the extremes.